<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30150348</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>28</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1757-790X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>2018</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>BMJ case reports</Title>                <ISOAbbreviation>BMJ Case Rep</ISOAbbreviation>            </Journal>            <ArticleTitle>Anti-AMPA receptor encephalitis associated with Medullary thyroid cancer.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">bcr-2018-225745</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2018-225745</ELocationID>            <Abstract>                <AbstractText>AMPA receptor (AMPAR) antibodies are a group of recently discovered antibodies which target the neuronal synaptic proteins causing B-cell (immune) mediated neuronal damage, resulting in various neurologic syndromes depending on the area of central nervous system involvement. These syndromes are mostly reversible if treated early. Tumour association has been reported in up to 60% of cases in the most recent case series with lung, breast, ovarian cancers and thymomas being the most commonly associated malignancies with these antibodies. We present here the first case of AMPAR encephalitis associated with medullary thyroid cancer. Our patient presented with cognitive dysfunction and behavioural changes over a period of 3 weeks, with a full recovery after starting immunotherapy, once the diagnosis of AMPAR limbic encephalitis was established. This case highlights the importance of early diagnosis and management of AMPAR encephalitis as these patients respond well to immunotherapy and can have an almost complete recovery.</AbstractText>                <CopyrightInformation>© BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Samad</LastName>                    <ForeName>Navira</ForeName>                    <Initials>N</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1160-1210</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Endocrinology, Monash Health, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wong</LastName>                    <ForeName>Jennifer</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Endocrinology, Monash Health, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMJ Case Rep</MedlineTA>            <NlmUniqueID>101526291</NlmUniqueID>            <ISSNLinking>1757-790X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">brainstem / cerebellum</Keyword>            <Keyword MajorTopicYN="N">cancer - see oncology</Keyword>            <Keyword MajorTopicYN="N">endocrine cancer</Keyword>            <Keyword MajorTopicYN="N">immunology</Keyword>            <Keyword MajorTopicYN="N">thyroid disease</Keyword>        </KeywordList>        <CoiStatement>Competing interests: None declared.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30150348</ArticleId>            <ArticleId IdType="pii">bcr-2018-225745</ArticleId>            <ArticleId IdType="doi">10.1136/bcr-2018-225745</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>